EUVIMEDEUVIMED entdecken
Crossref

Activation of CB2 Receptors by (−)-Cannabichromene but Not (+)-Cannabichromene

Michael Udoh, Marina Santiago iD, Syed Haneef, Alison Rodger, Charles K Marlowe, Philip J Barr, Mark Connor iD

Cannabis & Cannabinoid Research · 2025

DOI: 10.1089/can.2023.0212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cannabis & Cannabinoid Research, 2025. Verfasst von Michael Udoh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Macquarie Medical School, Macquarie University, North Ryde, Australia. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB2, Cannabinoids, Cannabinoid Receptor Agonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cannabichromene (CBC) is a minor constituent of cannabis that is a selective cannabinoid CB2 receptor agonist and activator of TRPA1. To date, it has not been shown whether (−)-CBC, (+)-CBC, or both can mediate these effects. In this study, we investigate the activity of the CBC enantiomers at CB1, CB2, and Transient receptor potential ankyrin 1 (TRPA1) receptors in vitro . Materials and Methods: CBC enantiomers were purified from synthetic CBC by chiral chromatography, and their optical activity was confirmed by spectroscopy. Human CB1 and CB2 receptor activity was measured using a fluorescent assay of membrane potential in stably transfected AtT20 cells. TRPA1 activation was measured using a fluorescent assay of intracellular calcium in stably transfected HEK293 cells.

Results

The (−)-CBC activated CB2 with an EC 50 of 1.5 µM, to a maximum of 60% of (−)CP55940. (+)-CBC did not activate CB2 at concentrations up to 30 µM. Only 30 µM (−)-CBC produced detectable activation of CB1, (+)-CBC was inactive. Both (−)-CBC and (+)-CBC activated TRPA1; at 30 µM (−)-CBC produced an activation 50% of that of the reference agonist cinnamaldehyde (300 µM), 30 µM (+)-CBC activated TRPA1 to 38% of the cinnamaldehyde maximum.

Discussion

It is unclear whether (−)-CBC is the sole or even the predominant enantiomer of CBC enzymatically synthesized in cannabis. This study shows that (−)-CBC is the active isomer at CB2 receptors, while both isomers activate TRPA1. The results suggest that medicinal preparations of CBC that target cannabinoid receptors would be most effective when (−)-CBC is the dominant isomer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Cannabinoid, CB2CannabinoidsCannabinoid Receptor AgonistsHumansHEK293 CellsStereoisomerismTRPA1 Cation ChannelReceptor, Cannabinoid, CB1AnimalsMembrane PotentialsCalciumMice

Stichwörter der Autor:innen

CB1CB2TRPA1cannabichromenechiral

Substanzen

Receptor, Cannabinoid, CB2CannabinoidsTRPA1 Cation ChannelcannabichromeneReceptor, Cannabinoid, CB1TRPA1 protein, humanCalciumCannabinoid Receptor Agonists

Autor:innen und Institutionen

  • Macquarie Medical School, Macquarie University, North Ryde, Australia.
  • School of Natural Sciences, Macquarie University, North Ryde, Australia.
  • Present address: Research School of Chemistry, Australian National University, ACT 2601, Australia.
  • A Division of InMed Pharmaceuticals, BayMedica, LLC, South San Francisco, California, USA.

ORCID-Profile: Marina Santiago, Mark Connor

Zitieren

APA

Udoh, M., Santiago, M., Haneef, S., Rodger, A., Marlowe, C. K., Barr, P. J., & Connor, M. (2025). Activation of CB2 Receptors by (−)-Cannabichromene but Not (+)-Cannabichromene. Cannabis & Cannabinoid Research. https://doi.org/10.1089/can.2023.0212

Vancouver

Udoh M, Santiago M, Haneef S, Rodger A, Marlowe CK, Barr PJ, et al. Activation of CB2 Receptors by (−)-Cannabichromene but Not (+)-Cannabichromene. Cannabis & Cannabinoid Research. 2025. doi:10.1089/can.2023.0212

BibTeX
@article{Udoh2025,
  author = {Udoh, Michael and Santiago, Marina and Haneef, Syed and Rodger, Alison and Marlowe, Charles K and Barr, Philip J and Connor, Mark},
  title = {Activation of CB2 Receptors by (−)-Cannabichromene but Not (+)-Cannabichromene},
  journal = {Cannabis & Cannabinoid Research},
  year = {2025},
  doi = {10.1089/can.2023.0212}
}
Kostenlos starten →